FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3028546912> ?p ?o ?g. }

• W3028546912 startingPage "27" @default.
• W3028546912 abstract "Regulation of cellular responses to interferons, cytokines, growth factors and hormones is mediated by signal transducer and activator of transcription (STAT) proteins. In the immune system binding of a cytokine (e.g. IFN) to the corresponding surface receptor, Janus kinase (JAK) molecules are phosphorylated, resulting in the docking and phosphorylation of the associated STAT proteins. The STATs will form homo or heterodimers and translocate to regulate transcription of pro-inflammatory target genes. Mutations in STAT1 are known to result in immunodeficiency and/or immune dysregulation syndromes. In this project, the functional impact of variants in the STAT1 gain-of-function gene (STAT1 GOF) will be analyzed on a protein level. The effect of a directed treatment approach targeting the JAK-STAT pathway (JAK inhibitors) will be evaluated in an in vitro model. Freshly isolated PBMCs or whole blood samples from patients and healthy controls were obtained. The cells were stimulated with IFNg and the treated with the JAK inhibitor Ruxolitinib. Extra and intracellular staining with anti-human fluorochrome conjugated antibodies was performed in order to determine the expression of STAT1 and pSTAT1 on monocytes by means of flow cytometry. Two pediatric patients and one related adult patient were studied and the pathogenicity of the variants was confirmed as STAT1 and pSTAT1 levels in the patients at baseline as well as after IFNg stimulation were markedly increased, when compared with healthy controls. The in vitro administration of different concentrations of the JAK inhibitor Ruxolitinib resulted in the normalization of pSTAT1 levels in the cells obtained from patients with STAT1 GOF mutations. Patients with STAT1 GOF mutations show a severe clinical phenotype with recurrent bacterial and fungal infections. Currently no specific treatment options are available. However recent case reports suggested the benefit of JAK inhibition. Therefore we studied the effect of this drug using primary cells in an in vitro model on a molecular level. Importantly two patients have been started on this medication and have achieved a significant clinical response. We are currently evaluating the capacity of our protocol to identify patients with alterations of the JAK-STAT pathway eligible for this targeted treatment approach." @default.
• W3028546912 created "2020-05-29" @default.
• W3028546912 creator A5009832583 @default.
• W3028546912 creator A5023836584 @default.
• W3028546912 creator A5046600042 @default.
• W3028546912 creator A5059930000 @default.
• W3028546912 creator A5090327640 @default.
• W3028546912 date "2020-01-01" @default.
• W3028546912 modified "2023-09-24" @default.
• W3028546912 title "Validation of STAT1 variants found in patients with primary immunodeficiencies and evaluation of the effect of JAK inhibition using an in vitro model." @default.
• W3028546912 hasPublicationYear "2020" @default.
• W3028546912 type Work @default.
• W3028546912 sameAs 3028546912 @default.
• W3028546912 citedByCount "0" @default.
• W3028546912 crossrefType "journal-article" @default.
• W3028546912 hasAuthorship W3028546912A5009832583 @default.
• W3028546912 hasAuthorship W3028546912A5023836584 @default.
• W3028546912 hasAuthorship W3028546912A5046600042 @default.
• W3028546912 hasAuthorship W3028546912A5059930000 @default.
• W3028546912 hasAuthorship W3028546912A5090327640 @default.
• W3028546912 hasConcept C112392421 @default.
• W3028546912 hasConcept C11960822 @default.
• W3028546912 hasConcept C145430368 @default.
• W3028546912 hasConcept C157333092 @default.
• W3028546912 hasConcept C171958077 @default.
• W3028546912 hasConcept C191732599 @default.
• W3028546912 hasConcept C203014093 @default.
• W3028546912 hasConcept C2776112149 @default.
• W3028546912 hasConcept C2777003663 @default.
• W3028546912 hasConcept C2778277574 @default.
• W3028546912 hasConcept C2778690821 @default.
• W3028546912 hasConcept C2778923194 @default.
• W3028546912 hasConcept C2779019163 @default.
• W3028546912 hasConcept C2779391668 @default.
• W3028546912 hasConcept C2780007613 @default.
• W3028546912 hasConcept C2780076729 @default.
• W3028546912 hasConcept C42362537 @default.
• W3028546912 hasConcept C62478195 @default.
• W3028546912 hasConcept C65439459 @default.
• W3028546912 hasConcept C86803240 @default.
• W3028546912 hasConcept C8891405 @default.
• W3028546912 hasConcept C95444343 @default.
• W3028546912 hasConceptScore W3028546912C112392421 @default.
• W3028546912 hasConceptScore W3028546912C11960822 @default.
• W3028546912 hasConceptScore W3028546912C145430368 @default.
• W3028546912 hasConceptScore W3028546912C157333092 @default.
• W3028546912 hasConceptScore W3028546912C171958077 @default.
• W3028546912 hasConceptScore W3028546912C191732599 @default.
• W3028546912 hasConceptScore W3028546912C203014093 @default.
• W3028546912 hasConceptScore W3028546912C2776112149 @default.
• W3028546912 hasConceptScore W3028546912C2777003663 @default.
• W3028546912 hasConceptScore W3028546912C2778277574 @default.
• W3028546912 hasConceptScore W3028546912C2778690821 @default.
• W3028546912 hasConceptScore W3028546912C2778923194 @default.
• W3028546912 hasConceptScore W3028546912C2779019163 @default.
• W3028546912 hasConceptScore W3028546912C2779391668 @default.
• W3028546912 hasConceptScore W3028546912C2780007613 @default.
• W3028546912 hasConceptScore W3028546912C2780076729 @default.
• W3028546912 hasConceptScore W3028546912C42362537 @default.
• W3028546912 hasConceptScore W3028546912C62478195 @default.
• W3028546912 hasConceptScore W3028546912C65439459 @default.
• W3028546912 hasConceptScore W3028546912C86803240 @default.
• W3028546912 hasConceptScore W3028546912C8891405 @default.
• W3028546912 hasConceptScore W3028546912C95444343 @default.
• W3028546912 hasIssue "9" @default.
• W3028546912 hasLocation W30285469121 @default.
• W3028546912 hasOpenAccess W3028546912 @default.
• W3028546912 hasPrimaryLocation W30285469121 @default.
• W3028546912 hasRelatedWork W1701936593 @default.
• W3028546912 hasRelatedWork W2042096192 @default.
• W3028546912 hasRelatedWork W2044268362 @default.
• W3028546912 hasRelatedWork W2051899176 @default.
• W3028546912 hasRelatedWork W2063462830 @default.
• W3028546912 hasRelatedWork W2093805697 @default.
• W3028546912 hasRelatedWork W2100162746 @default.
• W3028546912 hasRelatedWork W2122206270 @default.
• W3028546912 hasRelatedWork W2125719440 @default.
• W3028546912 hasRelatedWork W2143668961 @default.
• W3028546912 hasRelatedWork W2280140542 @default.
• W3028546912 hasRelatedWork W2565340012 @default.
• W3028546912 hasRelatedWork W2565567896 @default.
• W3028546912 hasRelatedWork W2581182536 @default.
• W3028546912 hasRelatedWork W2586638910 @default.
• W3028546912 hasRelatedWork W2924961288 @default.
• W3028546912 hasRelatedWork W2944778862 @default.
• W3028546912 hasRelatedWork W2945961964 @default.
• W3028546912 hasRelatedWork W2980915269 @default.
• W3028546912 hasRelatedWork W3159554490 @default.
• W3028546912 isParatext "false" @default.
• W3028546912 isRetracted "false" @default.
• W3028546912 magId "3028546912" @default.
• W3028546912 workType "article" @default.